The Dermatological Drugs market in Eastern Asia has been experiencing significant growth in recent years.
Customer preferences: One of the primary reasons for this growth is the increasing demand for dermatological drugs in the region. With a growing middle class and rising disposable incomes, more consumers are seeking treatment for skin conditions such as acne, eczema, and psoriasis. Additionally, there is a growing awareness of the importance of skincare and the use of preventative measures to maintain healthy skin.
Trends in the market: South Korea is one of the largest markets for dermatological drugs in Eastern Asia. This can be attributed to the country's strong focus on beauty and skincare, which has led to a high demand for products that address skin concerns. In recent years, there has been a trend towards natural and organic skincare products, as consumers become more conscious of the ingredients in their products. Japan is another significant market for dermatological drugs in the region, with a focus on anti-aging products and treatments.
Local special circumstances: China is also an important market for dermatological drugs, but the market is heavily regulated, and foreign companies face significant barriers to entry. Local companies dominate the market, and there is a preference for traditional Chinese medicine-based products. However, there is a growing interest in Western-style dermatological treatments, particularly among younger consumers.
Underlying macroeconomic factors: Overall, the growth of the dermatological drugs market in Eastern Asia can be attributed to a combination of factors, including rising disposable incomes, increasing awareness of skincare, and a growing middle class. Additionally, the aging population in many countries in the region has led to a higher demand for anti-aging treatments and products. As the region continues to develop and consumers become more educated about skincare, the market for dermatological drugs is expected to continue to grow.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
